MXPA05009667A - Compuestos heterociclicos inmunomoduladores. - Google Patents

Compuestos heterociclicos inmunomoduladores.

Info

Publication number
MXPA05009667A
MXPA05009667A MXPA05009667A MXPA05009667A MXPA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A
Authority
MX
Mexico
Prior art keywords
optionally substituted
alk
alkyl
radical
ring
Prior art date
Application number
MXPA05009667A
Other languages
English (en)
Inventor
Ian Richard Mathews
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of MXPA05009667A publication Critical patent/MXPA05009667A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la formula (I) son inhibidores de CD80 y son utiles en la terapia de inmunomodulacion:( ver formula (I)) en donde R1 y R3 representan independientemente H; F; Cl; Br; -NO2; -CN; alquilo de 1 a 6 atomos de carbono sustituido opcionalmente por F o Cl; o alcoxi de 1 a 6 atomos de carbono sustituido opcionalmente por F; R4 representa un grupo de acido carboxilico (-COOH) o un ester del mismo, o -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 o -NHC(=S)NR7R6, en donde R6 representa H, o un radical de la formula -(Alq)m-Q en donde m es 0 o 1, Alq es un radical de alquileno de 1 a 12 atomos de carbono o alquenilo de 2 a 12 atomos de carbono o alquinileno de 2 a 12 atomos de carbono de cadena recta o ramificada, divalente, sustituido opcionalmente o un radical carbociclico de 3 a 12 atomos de carbono, divalente, cualquiera de estos radicales puede contener una o mas uniones de -O-, -S- o -N(R8)-, en donde R8 representa H o alquilo de 1 a 4 atomos de carbono, alquenilo de 3 a 4 atomos de carbono, alquinilo de 3 a 4 atomos de carbono o cicloalquilo de 3 a 6 atomos de carbono y Q representa H; -NR9R10, en donde R9 y R10 representan independientemente H; alquilo de 1 a 4 atomos de carbono; alquenilo de 3 a 4 atomos de carbono; alquinilo de 3 a 4 atomos de carbono; cicloalquilo de 3 a 6 atomos de carbono; un grupo ester; un grupo carbociclico o heterociclico sustituido opcionalmente; o R9 y R10 forman un anillo cuando se toman junto con el atomo de nitrogeno al cual estan unidos, anillo que es sustituido opcionalmente; y R7 representa H o alquilo de 1 a 6 atomos de carbono; o cuando se toma junto con el atomo o atomos a los cuales estan unidos R6 y R7 forman un anillo heterociclico, monociclico, sustituido opcionalmente que tiene 5, 6 o 7 atomos del anillo; y X representa un enlace o un radical divalente de la formula -(Z)n-(Alq)- o -(Alq)-(Z)n- en donde Z representa -O-, -S- o -NH-, Alq es como se define con relacion a R6 y n es 0 o 1.
MXPA05009667A 2003-03-14 2004-03-10 Compuestos heterociclicos inmunomoduladores. MXPA05009667A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds
PCT/GB2004/001008 WO2004081011A1 (en) 2003-03-14 2004-03-10 Immunomodulating heterocyclic compounds

Publications (1)

Publication Number Publication Date
MXPA05009667A true MXPA05009667A (es) 2006-01-27

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009667A MXPA05009667A (es) 2003-03-14 2004-03-10 Compuestos heterociclicos inmunomoduladores.

Country Status (20)

Country Link
US (3) US7276505B2 (es)
EP (2) EP1603917B1 (es)
JP (1) JP4892338B2 (es)
KR (1) KR101133959B1 (es)
AT (1) ATE489388T1 (es)
BR (1) BRPI0408365B8 (es)
CA (1) CA2519063C (es)
DE (1) DE602004030225D1 (es)
DK (1) DK1603917T3 (es)
EA (2) EA014080B1 (es)
EC (1) ECSP056104A (es)
HK (1) HK1090921A1 (es)
IL (1) IL170389A (es)
MX (1) MXPA05009667A (es)
NO (1) NO332136B1 (es)
NZ (1) NZ541973A (es)
PL (2) PL1603917T3 (es)
PT (1) PT1603917E (es)
SI (1) SI1603917T1 (es)
WO (1) WO2004081011A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1603917T3 (pl) * 2003-03-14 2011-12-30 Medigene Ag Związki heterocykliczne o właściwościach immunomodulujących
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
EP1912970A2 (en) * 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
MX2008014743A (es) 2006-05-19 2008-12-01 Wyeth Corp N-benzoil- y n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3.
WO2008004610A1 (fr) * 2006-07-05 2008-01-10 The University Of Tokyo Méthode de traitement de maladie génétique provoquée par une mutation non sens
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010533725A (ja) 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐3(h3)受容体としてのアミノアルキルアゾール化合物
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
ES2460897T3 (es) 2007-10-04 2014-05-14 F. Hoffmann-La Roche Ag Derivados de ciclopropil aril amida y usos de los mismos
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
WO2018110669A1 (en) 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) * 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔4,3−c〕シンノリン−3−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) * 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
EP1411052B1 (en) 2001-07-05 2011-10-05 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7081456B2 (en) 2002-11-22 2006-07-25 Active Biotech Ab Immunomodulatory compounds
WO2004055014A1 (en) 2002-12-16 2004-07-01 Active Biotech Ab Tetracyclic immunomodulatory compounds
PL1603917T3 (pl) * 2003-03-14 2011-12-30 Medigene Ag Związki heterocykliczne o właściwościach immunomodulujących
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
CA2519063A1 (en) 2004-09-23
US7598247B2 (en) 2009-10-06
SI1603917T1 (sl) 2011-04-29
HK1090921A1 (en) 2007-01-05
PL383655A1 (pl) 2008-04-14
DE602004030225D1 (de) 2011-01-05
EA200702435A1 (ru) 2008-06-30
US20070021428A1 (en) 2007-01-25
NO20054710D0 (no) 2005-10-13
DK1603917T3 (da) 2011-02-28
BRPI0408365A (pt) 2006-03-21
US20080045527A1 (en) 2008-02-21
EA200501370A1 (ru) 2006-08-25
ATE489388T1 (de) 2010-12-15
EP2284172A1 (en) 2011-02-16
EP1603917B1 (en) 2010-11-24
CA2519063C (en) 2011-05-10
IL170389A (en) 2013-08-29
US8309552B2 (en) 2012-11-13
NZ541973A (en) 2009-06-26
US7276505B2 (en) 2007-10-02
BRPI0408365B8 (pt) 2021-05-25
WO2004081011A1 (en) 2004-09-23
KR101133959B1 (ko) 2012-04-09
JP4892338B2 (ja) 2012-03-07
KR20050121681A (ko) 2005-12-27
PT1603917E (pt) 2011-02-04
US20090312334A1 (en) 2009-12-17
JP2006520372A (ja) 2006-09-07
EA009680B1 (ru) 2008-02-28
EA014080B1 (ru) 2010-08-30
PL1603917T3 (pl) 2011-12-30
ECSP056104A (es) 2006-03-01
NO332136B1 (no) 2012-07-02
BRPI0408365B1 (pt) 2018-11-21
EP1603917A1 (en) 2005-12-14
NO20054710L (no) 2005-12-13
AU2004220310A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
MXPA05009667A (es) Compuestos heterociclicos inmunomoduladores.
NZ505638A (en) Bicyclic pyrrole derivatives as MCP-1 inhibitors
MY144718A (en) Viral polymerase inhibitors.
MXPA04002602A (es) Compuestos de ester y sus usos medicos.
EA200600509A1 (ru) Соединения пиримидотиофена
NO931433L (no) 4,1-benzoksazepinderivater og deres anvendelse
AR018892A1 (es) Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis
ES2531149T3 (es) Derivados de 2-piridiniletilcarboxamida y su uso como fungicidas
ATE538780T1 (de) Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum
PE20030969A1 (es) Compuestos heterociclicos, activos inhibidores de beta-lactamasas
WO2005095395A3 (en) Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
TW200617003A (en) Viral polymerase inhibitors
ES2184268T3 (es) Oligomeros de organosilanos.
NO20061126L (no) Aminopyroner og deres anvendelse som ATM-inhibitorer
NZ335157A (en) N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
EA200900616A1 (ru) Ингибиторы ikk-бета серин-треонин протеинкиназы
TW200612931A (en) Substituted biphenyl derivatives
HK1048303A1 (en) Aminobenzophenoses as inhibitors of il-1b and tnf -a.
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
UA49005C2 (uk) Похідні камптотецину (варіанти), спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
MXPA06001039A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
ATE215555T1 (de) 17-beta.-allyloxy(thio)alkyl-androstan derivative zur modulation von meiose
YU73202A (sh) Novi proces za sintezu n-/(s)-1-karboksibutil/-(s)- alaninskog estra i primena u sintezi perindoprila
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration
GB Transfer or rights